Publication: Importance of pharmacogenetics in the treatment of children with attention deficit hyperactive disorder: A case report
Issued Date
2013-01-10
Resource Type
ISSN
11787066
Other identifier(s)
2-s2.0-84872837504
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Pharmacogenomics and Personalized Medicine. Vol.6, No.1 (2013), 3-7
Suggested Citation
Teerarat Tan-kam, Chutamanee Suthisisang, Chosita Pavasuthipaisit, Penkhae Limsila, Apichaya Puangpetch, Chonlaphat Sukasem Importance of pharmacogenetics in the treatment of children with attention deficit hyperactive disorder: A case report. Pharmacogenomics and Personalized Medicine. Vol.6, No.1 (2013), 3-7. doi:10.2147/PGPM.S36782 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/31377
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Importance of pharmacogenetics in the treatment of children with attention deficit hyperactive disorder: A case report
Other Contributor(s)
Abstract
This case report highlights the importance of pharmacogenetic testing in the treatment of attention deficit hyperactive disorder (ADHD). A 6-year-old boy diagnosed with ADHD was prescribed methylphenidate 5 mg twice daily (7 am and noon) and the family was compliant with administration of this medication. On the first day of treatment, the patient had an adverse reaction, becoming disobedient, more mischievous, erratic, resistant to discipline, would not go to sleep until midnight, and had a poor appetite. The All-In-One PGX (All-In-One Pharmacogenetics for Antipsychotics test for CYP2D6, CYP2C19, and CYP2C9) was performed using microarray-based and real-time polymerase chain reaction techniques. The genotype of our patient was identified to be CYP2D6*2/*10, with isoforms of the enzyme consistent with a predicted cytochrome P450 2D6 intermediate metabolizer phenotype. Consequently, the physician adjusted the methylphenidate dose to 2.5 mg once daily in the morning. At this dosage, the patient had a good response without any further adverse reactions. Pharmacogenetic testing should be included in the management plan for ADHD. In this case, cooperation between the medical team and the patients' relatives was key to successful treatment. © 2013 Tan-kam et al, publisher and licensee Dove Medical Press Ltd.